Skip Navigation U.S. Department of Health and Human Services
Agency for Healthcare Research Quality
Archive print banner

This information is for reference purposes only. It was current when produced and may now be outdated. Archive material is no longer maintained, and some links may not work. Persons with disabilities having difficulty accessing this information should contact us at: Let us know the nature of the problem, the Web address of what you want, and your contact information.

Please go to for current information.

Table 6. Thalidomide Efficacy Studies—Studies of Thalidomide Plus Other Agents in Newly Diagnosed and/or Previously Untreated Multiple Myeloma

Study ID

Thalidomide Dose Daily
[Median length of followup]

No. of Patients, Age, Sex, additional MM characteristics


Paraprotein Response


Phase III

*Facon, 2004 (ASH 206)78


Up to 400 mg
MP vs. MPT vs. MEL100:

Arm A=Standard MP (assumed—exact MP regimen not stated: melphalan 4 mg/m2 po d1-7; prednisone 40 mg/m2 d1-7 q6 wk x 12)

Arm B=MPT=same MP + Thal up to 400 mg

Arm C=MEL100=VAD x 2 + melphalan 100 mg/m2 iv x 2 (w/ cyclophosphamide 3g/m2 for stem cell collection)
[12 mos]

200—Enrollment ongoing (goal N=500)

Inclusion=age 65-75 yr
Actual age & gender of enrolled pts=NS


Not reported

Planned interim analysis at N=200 for safety

Shows no clear advantage or disadvantage of either MP-Thal or MEL100 over MP.

*Palumbo, 2004 (ASH 207)79


100 mg
MPT vs. MP:
melphalan 4 mg/m2 po + prednisone 40 mg/m2 d1-7 q mo ±Thalidomide 100 mg
Not randomized
enoxaparin prophylaxis added after trial started
[15 mo]

200—Enrollment appears complete
72 yr (56-85)

Gender not specified
Newly diagnosed MM
MM characteristics=NS

102 evaluable at time of report

Overall Response (≥25%)=UTD

m protein reduction:

After MPT:
   Near CR=5.5%

After MP:
   Near CR=0%

EFS @ 26 mos:
   EFS w/MPT=67.8%
   EFS w/MP=32.4%

OS not reached

Treatment related mortality:

Adverse events:

  DVT: MPT 19%, MP 2%
  Infections (Grade 3/4): MPT 13%, MP 2%
  Neurotoxicity (Grade 1/2): MPT 36%, MP 5%
  Hem. toxicity (Grade 3/4): MPT 23%, MP 28%

Phase II

*Alexanian, 2004 (ASH 210)80


100-200 mg
VTD: Velcade (Bortezomib) 1.0-1.9 mg/m2 d1, 4, 8 & 11
Thal 100-200 mg
Dex 20 mg/m2 q4d d1, 9, 17
Repeat VTD q4 wk
[6 mo (2-14)]

63 yr (39-81)

Gender not specified
Previously untreated
MM characteristics=NS


Overall Response (≥25%)=UTD

m protein reduction:

Median time to remission=0.6 mo (0.3-1.8)

Autologous blood stem cells easily collected in 12 pts who were intensified for a median 3.6 mo after initial therapy

*Chanan-Khan, Miller, McCarthy, Koryzna, et al, 2004 (ASH 3463)81


100-200 mg
VAD d1-4 qmo + Thal 100-200 mg
Repeat q 4wk x 4 cycles
Coumadin 1-2 mg for DVT prophylaxis
[Median f/u=NS]

58 yr (46-77)
50% M

>Stage 1
No prior therapy
Stage III=69%

11 evaluable

Overall Response (≥25%)=91%

m protein reduction:


*Dimopoulos, 2004 (ASH 1482)82


300 mg
MDT: Melphalan 8 mg/m2 d-4, Dexamethasone 12 mg/m2 d1-4, 14-18
Thal 300 mg. d1-4, 14-18
Repeated q5wk x 10 cycles
[15 mo]

43—Enrollment ongoing (goal N=NS)
78 yr (75-85)

No prior therapy
Inclusion=Symptomatic MM with age ≥75 yr
Stage III=58%
Other MM characteristics=NS


Overall Response (≥25%)=72%

m protein reduction:

Median time to PR=2 mo (0-5-5.5)

OS @ 15 mo median f/u=88%

*Hassoun, 2004 (ASH 2409)83


AD/TD=Doxorubicin/Dex followed by Thal/Dex
Doxorubicin=9 mg/m2 d1-4, Dex=40 mg/d, d1-4, 9-12, 17-20;
Thal=200 mg
Dex as above

38—Enrollment ongoing (goal N=NS)
59 yr (35-82)
58% M

Stage II & III symptomatic MM
MM characteristics=NS


Overall Response (≥25%)=86.6%

m protein reduction:


*Klueppelberg, 2004 (ASH 4932)84;
*Klueppelberg, 2004 (ASCO 6702)85;
*Klueppelberg, 2005 (ASCO 6697)86


3 reports of ongoing study with increasing enrollment; most data presented here from most recent report with highest n

100 mg
Thal 100 mg + Dex 10-40 mg d1-4, 9-12, 17-20 for 6 mo then d1-4 qmo +zoledronate 4mg qmo
[Mean time on TDZ= 12 mo; 13 pts followed for 12-24 mo]

61 yr (43-82)
73% F

Newly diagnosed MM
Stage III=69%
Other MM characteristics=NS

29 evaluable

Overall Response (≥25%)=90%

m protein reduction:

Cumulative probability of ≥25% PPR=73% (± 20.6%) within 10 mo

Responses were unaffected to HIV status or antiviral treatment

Median time to response=5.9 mo

Age-adjusted 1-year OS=74$

Schutt, 200587

Quality 5/5

200-400 mg
Thal-VED: Thal starting at 200 mg and increasing to 400 mg/d + vincristine 1.5 mg d1 + epirubicin 30mg/m2/d d1-2 + Dex 20 mg/m2/d d1-5
Repeated q3wk
Mean # cycles=4 (1-8)
[Median f/u=NS]

57 yr (32-77)
68% M

Untreated MM
Stage III=91%
B-J protein=16%


Overall Response (≥25%)=80%

m protein reduction:

EFS @ 36mo=26%

OS @ 36 mo=62%

Med EFS=36 mo

Med OS not reached at 40 mo

Max response to treatment achieved by median 2.8 mo (1.4-7.2 mo)

20 were candidates for SCT and PBSC were collected In all

Zervas, 200488

Quality 3/5

200 mg
+ VAD + Dex 40 mg/m2 x 4d on d15 of cycle 1 only
VAD: VCR 2mg Liposomal doxorubicin 40 mg/m2
Dex 40 mg/m2 qdx4
[10 mo, 2-22]

68 yr (43-75)
51% M

Newly diagnosed with symptomatic MM,
Stage III=64%
Light chain=13%


Overall Response (≥25%)=82%

m protein reduction:

EFS @ 22 mo=55%

OS @ 22 mo=74%

6 Early deaths:
   4=disease progression
   2=neutropenic infection

38% proceeded to SCT (47% of responders)

Abbreviations: *=abstract, AD/TD=Doxorubicin/Dex + Thal/Dex, alloBMT=allogeneic bone marrow transplant, B-J=Bence Jones protein, CR=Complete Response, Dex=Dexamethasone, DVT=Deep venous thrombosis, EFS=event free survival, f/u=followup, Hem=hematologic, HIV+=Human Immunodeficiency Virus Positive, IFN=Interferon, MP=melphalan/prednisone, MPT=MP + Thal, Near CR=positive IFE only, NS=not stated, OS=overall survival, PFS=progression free survival, PPR=Paraprotein reduction, PR=partial response, pt(s)=patient(s), SCT=stem cell transplant, T=Thalidomide, TDZ=Thal/Dex/Zoledronate, UTD=unable to determine, VAD=standard chemotherapy including Vincristine/Doxorubicin/Dexamethasone, V=Velcade (Bortezomib), VCR=Vincristine, VED=combination chemotherapy including Vincristine/Etoposide/Dex, VTD=Velcade/Thal/Dex

Return to Document
Proceed to Next Table

The information on this page is archived and provided for reference purposes only.


AHRQ Advancing Excellence in Health Care